A novel mRNA drug, 3’UTRMYC1-18 (UTRxM1-18), has demonstrated notable efficacy in preclinical models of aggressive pancreatic cancer, addressing a disease that is often resistant to conventional treatments.

UTR Therapeutics Inc. has submitted an IND application to the FDA for UTRxM1-18, a novel therapeutic approach for targeting c-MYC-driven cancers. Pending approval, a first-in-human phase I trial is slated to begin next year.